• Orakl Oncology raised $34 million in Series A financing on November 12, 2026, bringing total funding to $50 million.
• Norrsken VC and Singular co-led the oversubscribed round, with InfraVia participating as a new investor.
• The oncology company uses AI and patient-derived tumor models to predict cancer drug performance before clinical trials.
• Its predictive engine demonstrated 90% accuracy in forecasting cancer clinical trial outcomes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Infravia Capital Partners SAS published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.